Mirna Therapeutics Inc (NASDAQ:MIRN)‘s stock had its “neutral” rating reissued by analysts at Leerink Swann in a research note issued to investors on Wednesday.

The analysts wrote, “We maintain our Market Perform rating for Amgen along with our $193 price target.””

Other research analysts have also issued research reports about the stock. HC Wainwright began coverage on shares of Mirna Therapeutics in a research report on Monday, September 12th. They issued a “buy” rating and a $6.00 price target on the stock. Zacks Investment Research upgraded shares of Mirna Therapeutics from a “hold” rating to a “buy” rating and set a $2.75 price target on the stock in a research report on Wednesday, September 7th. Citigroup Inc. lowered shares of Mirna Therapeutics from a “buy” rating to a “neutral” rating and decreased their price target for the stock from $7.00 to $4.50 in a research report on Tuesday, August 16th. Oppenheimer Holdings Inc. lifted their price target on shares of Mirna Therapeutics from $7.00 to $13.00 and gave the stock an “outperform” rating in a research report on Tuesday, August 16th. Finally, Cantor Fitzgerald lowered shares of Mirna Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the company. Mirna Therapeutics has a consensus rating of “Hold” and a consensus target price of $7.38.

Analyst Recommendations for Mirna Therapeutics (NASDAQ:MIRN)

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/21/mirna-therapeutics-mirn-neutral-rating-reiterated-at-leerink-swann.html

Mirna Therapeutics (NASDAQ:MIRN) traded down 23.17% during mid-day trading on Wednesday, hitting $1.89. The stock had a trading volume of 134,484 shares. The stock’s market cap is $39.38 million. Mirna Therapeutics has a one year low of $1.82 and a one year high of $11.01. The firm’s 50-day moving average is $3.17 and its 200 day moving average is $4.12.

Mirna Therapeutics Company Profile

Mirna Therapeutics, Inc is a clinical-stage biopharmaceutical company developing a pipeline of micro ribonucleic acid (RNA)-based oncology therapeutics. The Company is developing mimics of naturally occurring microRNAs that are designed to restore the tumor suppressor activity and aid appropriate anti-tumor immune response.

5 Day Chart for NASDAQ:MIRN

Receive News & Ratings for Mirna Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirna Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.